California Public Employees Retirement System reduced its stake in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 9.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,200 shares of the medical research company’s stock after selling 6,000 shares during the period. California Public Employees Retirement System owned about 0.18% of Genomic Health worth $1,896,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the stock. Dubuque Bank & Trust Co. acquired a new stake in Genomic Health during the first quarter valued at about $142,000. Russell Investments Group Ltd. acquired a new stake in Genomic Health during the fourth quarter valued at about $575,000. Norges Bank acquired a new stake in Genomic Health during the fourth quarter valued at about $4,546,000. American International Group Inc. boosted its position in shares of Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock valued at $362,000 after buying an additional 765 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in shares of Genomic Health by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock valued at $935,000 after buying an additional 1,838 shares in the last quarter. 88.54% of the stock is currently owned by institutional investors.
Genomic Health, Inc. (NASDAQ GHDX) opened at 29.59 on Friday. Genomic Health, Inc. has a 1-year low of $25.66 and a 1-year high of $33.97. The firm has a 50-day moving average of $31.85 and a 200-day moving average of $31.25. The stock’s market cap is $1.03 billion.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.02. The firm had revenue of $85.50 million for the quarter, compared to analysts’ expectations of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.18) earnings per share. Analysts expect that Genomic Health, Inc. will post ($0.01) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/19/california-public-employees-retirement-system-has-1-90-million-position-in-genomic-health-inc-ghdx-updated-updated.html.
Several equities analysts recently commented on the stock. Canaccord Genuity reduced their price objective on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday. BidaskClub cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Zacks Investment Research cut shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $33.00 price objective on shares of Genomic Health in a research note on Monday, June 12th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the stock. Genomic Health has an average rating of “Hold” and a consensus price target of $32.00.
In other Genomic Health news, insider Kimberly J. Popovits sold 5,000 shares of Genomic Health stock in a transaction on Monday, June 5th. The shares were sold at an average price of $32.32, for a total transaction of $161,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James J. Vaughn sold 8,000 shares of Genomic Health stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $30.59, for a total transaction of $244,720.00. The disclosure for this sale can be found here. Insiders have sold 47,642 shares of company stock valued at $1,503,731 over the last ninety days. 46.20% of the stock is owned by insiders.
About Genomic Health
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
What are top analysts saying about Genomic Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health Inc. and related companies.